Women with moderate to severe fibroids set to be offered new one-a-day treatment following final draft guidance from NICE

Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (also called Ryeqo and made by Gedeon Ritcher UK) in final draft guidance.

Read news story

  1. NICE outlines steps needed to put ME/CFS guideline into practice

    NICE has today, International ME Awareness Day (Thursday, 12 May 2022) published its implementation statement which sets out the practical steps needed to put its recent guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) into


NICE Talks podcasts

NICE Talks brings you the real life experiences of people working within the NHS, public health and social care.

You will hear the stories behind our work to improve care across the country through evidence-based guidance.

Press and media

Contact the press office: 07973 970 534 |